Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018TM Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen
Authors:
- Sakshi BajoriaSBSakshi Bajoria
- Ozan S. KumruOKOzan S. Kumru
- Jennifer DoeringJDJennifer Doering
- Katherine BermanKBKatherine Berman
- Greta Van SlykeGSGreta Van Slyke
- Anneka PrigodichAPAnneka Prigodich
- Sergio A. Rodriguez-AponteSRSergio A. Rodriguez-Aponte
- Harry KleanthousHKHarry Kleanthous
- J. Christopher LoveJLJ. Christopher Love
- Nicholas J. MantisNMNicholas J. Mantis
- Sangeeta B. JoshiSJSangeeta B. Joshi
- David B. VolkinDVDavid B. Volkin
Open Access
Abstract
Aluminum-salt vaccine adjuvants (alum) are commercially available as micron-sized particles with varying chemical composition and crystallinity. There are reports of enhanced adjuvanticity when the alum’s particle size is reduced to the nanometer range. Previously, we demonstrated that a recombinant receptor-binding domain (RBD)-based COVID-19 vaccine candidate (RBD-J; RBD-L452K-F490W) formulated with aluminum hydroxide (Alhydrogel®; AH) and CpG 1018™ (CpG) adjuvants induced potent neutralizing antibody responses in mice yet displayed instability during storage. In this work, we evaluated whether sonication of AH to the nanometer size range (nanoAH) could further enhance immunogenicity or improve storage stability of the above formulation. The addition of CpG to nanoAH (at mouse doses), however, caused re-agglomeration of nanoAH. AH-CpG interactions were evaluated by Langmuir binding isotherms and zeta potential measurements, and stabilized nanoAH + CpG formulations of RBD-J were then designed by (1) optimizing CpG:Aluminum dose ratios or (2) adding a small-molecule polyanion (phytic acid, PA). Compared with the micron-sized AH + CpG formulation, the two stabilized nanoAH + CpG formulations of RBD-J demonstrated no enhancement in SARS-CoV-2 pseudovirus neutralizing titers in mice, but the PA-containing nanoAH + CpG formulation showed improved RBD-J storage stability trends (at 4, 25, and 37 °C). The formulation protocols presented herein can be employed to evaluate the potential benefits of the nanoAH + CpG adjuvant combination with other vaccine antigens in different animal models.Keywords
Funding Information
- Bill & Melinda Gates Foundation (INV-002740, INV-027417)
This publication has 36 references indexed in Scilit:
- Vaccine Potentiation by Combination AdjuvantsVaccines, 2014
- Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticlesJournal of Controlled Release, 2014
- Engineering an Effective Immune Adjuvant by Designed Control of Shape and Crystallinity of Aluminum Oxyhydroxide NanoparticlesACS Nano, 2013
- Mechanism of Immunopotentiation and Safety of Aluminum AdjuvantsFrontiers in Immunology, 2013
- Alum adjuvant: some of the tricks of the oldest adjuvantJournal of Medical Microbiology, 2012
- Alhydrogel® adjuvant, ultrasonic dispersion and protein binding: A TEM and analytical studyMicron, 2012
- Effect of ultrasonication and dispersion stability on the cluster size of alumina nanoscale particles in aqueous solutionsUltrasonics Sonochemistry, 2011
- Nanoparticles target distinct dendritic cell populations according to their sizeEuropean Journal of Immunology, 2008
- Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiationExpert Review of Vaccines, 2007
- Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitroVaccine, 2005